Spain Brazil Russia France Germany China Korea Japan

Artificial Intelligence driven Marketing Communications

Sep 14, 2020 12:36 PM ET

Silence Therapeutics Reports Interim Results for the Six Months Ended 30 June 2020

iCrowd Newswire - Sep 14, 2020

Silence Therapeutics plc, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces its unaudited interim results for the half year to 30 June 2020.

Business Highlights for H1 2020

Financial Highlights

Post Period Events

Iain Ross, Chairman of Silence Therapeuticscommented: “The first half of 2020 was an extraordinary period for Silence, highlighted by significant regulatory achievements, advancement of our proprietary pipeline programmes and execution of major collaborations with AstraZeneca and Takeda, despite the challenges posed by the COVID-19 pandemic. Our balance sheet was significantly strengthened through non-dilutive strategic transactions and our team enhanced with key hires throughout the organisation. 

Recently we announced our successful listing on Nasdaq and today we are announcing the appointment of our new President and CEO, Mark Rothera. I am incredibly proud of what we have achieved so far this year and I believe that under Mark’s leadership we are well equipped to drive long-term value. I would like to thank the entire Silence team for their dedication, resilience and personal support during my time as Executive Chairman and our shareholders for their continued support.”


Silence Therapeutics plc
Iain Ross, Chairman
Dr Rob Quinn, Chief Financial Officer


Tel:  +44 (0)20 3457 6900
  Investec Bank plc (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence


  Tel:  +44 (0) 20 7597 5970
European IR
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray


Tel: +44 (0) 20 3709 5700
Westwicke Partners
Peter Vozzo


 Tel: +1 (443) 213-0505

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence’s proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassaemia and myelodysplastic syndrome. Silence is also developing SLN500 in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases.  Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit:

Call for analysts and investors

Iain Ross, Executive Chairman, Mark Rothera, Chief Executive Officer, Dr Rob Quinn, Chief Financial Officer and Dr. Giles Campion, Head of R&D and Chief Medical Officer will host a webcast and live conference call for analysts and investors at 13:00 BST | 08:00 ET today.

Details of the webcast and conference call:

Webcast link:

Dial-in Details:
United Kingdom               08002796619
United States                    18778709135
Conference ID                   7577462

Contact Information:

Westwicke Partners
Peter Vozzo

Tags:    Wire, Disclosure Newswire, United States, English